search
Back to results

Optimized Perioperative Antibiotic Prophylaxis in Radical Cystectomy (PAPRAC)

Primary Purpose

Radical Cystectomy, Surgical Site Infection, Urologic Cancer

Status
Active
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Short PAP
Extended PAP
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Radical Cystectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent
  • Age >18 years
  • Planned radical cystectomy at the Department of Urology, Bern University Hospital

Exclusion Criteria:

  • Contraindications to the classes of drugs under study, e.g. known hypersensitivity or allergy to class of drugs including alternatives described in the protocol or the investigational product,
  • Women who are pregnant or breast feeding (exclusion for surgery),
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons,

Sites / Locations

  • Department of Infectious Diseases, University Hospital Bern
  • Department of Urology, University Hopspital Bern

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Short PAP

Extended PAP

Arm Description

Perioperative antibiotic prophylaxis will be stopped after 24h

Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)

Outcomes

Primary Outcome Measures

Rate of Surgical Site infections (SSI)
Rate of surgical site infections occurring within 90 days post surgery will be calculated for each patient.
Time to event of SSI
Time to event of SSI (event free survival analysis)
Rate of Urinary tract infections (UTI)
Rate of urinary tract infections occurring within 90 days post surgery will be calculated for each patient.
Time to event of UTI
Time to event of UTI (event free survival analysis)

Secondary Outcome Measures

Rate and type of Antibiotic associated adverse events (AEs)
Rates and types of antibiotic associated AEs occurring within 30 days post surgery (direct AEs such as hypersensitivity reaction, hepatotoxicity, renal toxicity etc and indirect AEs such as line associated infections, C.difficile diarrhoea) will be assessed for each patient.
Frequency of multi-drug-resistant bacteria in urinary samples
The frequency of multi-drug-resistant bacteria in urine samples obtained at predefined time points during the first 30 days post surgery will be calculated for each patient
Changes in fecal flora
Changes in the composition of the fecal flora will be assessed in fecal samples collected at pre-specified time points
Antibiotic associated costs
Directly antibiotic associated costs incurred during 30days post surgery will be assessed

Full Information

First Posted
September 27, 2017
Last Updated
January 23, 2023
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT03305627
Brief Title
Optimized Perioperative Antibiotic Prophylaxis in Radical Cystectomy
Acronym
PAPRAC
Official Title
Optimized Perioperative Antibiotic Prophylaxis in Radical Cystectomy
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 9, 2018 (Actual)
Primary Completion Date
October 30, 2022 (Actual)
Study Completion Date
June 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Cystectomy with urinary diversion (ileal conduit, orthotopic ileal bladder substitute, continent catheterizable pouch) is the best treatment option for patients with muscle-invasive bladder cancer. This intervention is one of the most challenging in urology and has a high rate of postoperative complications including around 30% of postoperative infections. Perioperative antibiotic prophylaxis (PAP) is widely accepted as a crucial preventive measure to reduce the incidence of surgical site infections (SSI). The rationale for PAP is the reduction of the local bacterial load at the site and time of intervention, and therefore a short duration of PAP of 24 to maximal 48 hours is recommended for all clean to clean-contaminated procedures.. Evidence supporting the optimal duration of PAP for radical cystectomy with urinary diversion is lacking. Based on data extrapolated from abdominal surgery, current guidelines recommend short-term PAP (≤24h) for all clean-contaminated procedures including radical cystectomy. However, a recent evaluation revealed a significant inter-hospital variability of PAP and showed that extended use (>48h) was common in patients undergoing radical cystectomy. Importantly, this study also demonstrated that longer duration of PAP incurred higher costs and was associated with an increased rate of C. difficile colitis. A small, prospective, non-randomized study showed equal efficacy of short-term PAP in preventing postoperative infections in patients undergoing radical cystectomy with ileum conduit compared to extended PAP. Nonetheless, larger randomized clinical trials supporting these findings are lacking. The unwarranted extended use of antibiotics is a major concern as exposure to antibiotics is a driving force for the development of (multi-) resistant bacteria and will lead to an increasing number of difficult-to-treat infections. This has been recognized on both national and international levels and is addressed within antimicrobial stewardship frameworks. This study will compare current practice (>48h PAP, "extended PAP") with the guideline recommended approach (24h PAP, "short term PAP") in a single-centre, prospective, randomised clinical non-inferiority trial. The primary outcome is the rate of SSI within 90 days post surgery. The aim of the study is to generate currently lacking evidence allowing for an optimised PAP strategy in a challenging surgical setting.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radical Cystectomy, Surgical Site Infection, Urologic Cancer, Perioperative/Postoperative Complications, Antibiotic Resistant Infection, Antibiotic Side Effect, Antibiotic-associated Diarrhea

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
196 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Short PAP
Arm Type
Experimental
Arm Description
Perioperative antibiotic prophylaxis will be stopped after 24h
Arm Title
Extended PAP
Arm Type
Active Comparator
Arm Description
Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)
Intervention Type
Other
Intervention Name(s)
Short PAP
Intervention Description
Perioperative antibiotic prophylaxis for 24h
Intervention Type
Other
Intervention Name(s)
Extended PAP
Intervention Description
Perioperative antibiotic prophylaxis for >48h
Primary Outcome Measure Information:
Title
Rate of Surgical Site infections (SSI)
Description
Rate of surgical site infections occurring within 90 days post surgery will be calculated for each patient.
Time Frame
90 days
Title
Time to event of SSI
Description
Time to event of SSI (event free survival analysis)
Time Frame
90 days
Title
Rate of Urinary tract infections (UTI)
Description
Rate of urinary tract infections occurring within 90 days post surgery will be calculated for each patient.
Time Frame
90 days
Title
Time to event of UTI
Description
Time to event of UTI (event free survival analysis)
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Rate and type of Antibiotic associated adverse events (AEs)
Description
Rates and types of antibiotic associated AEs occurring within 30 days post surgery (direct AEs such as hypersensitivity reaction, hepatotoxicity, renal toxicity etc and indirect AEs such as line associated infections, C.difficile diarrhoea) will be assessed for each patient.
Time Frame
30 days
Title
Frequency of multi-drug-resistant bacteria in urinary samples
Description
The frequency of multi-drug-resistant bacteria in urine samples obtained at predefined time points during the first 30 days post surgery will be calculated for each patient
Time Frame
30 days
Title
Changes in fecal flora
Description
Changes in the composition of the fecal flora will be assessed in fecal samples collected at pre-specified time points
Time Frame
30 days
Title
Antibiotic associated costs
Description
Directly antibiotic associated costs incurred during 30days post surgery will be assessed
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent Age >18 years Planned radical cystectomy at the Department of Urology, Bern University Hospital Exclusion Criteria: Contraindications to the classes of drugs under study, e.g. known hypersensitivity or allergy to class of drugs including alternatives described in the protocol or the investigational product, Women who are pregnant or breast feeding (exclusion for surgery), Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, Previous enrolment into the current study, Enrolment of the investigator, his/her family members, employees and other dependent persons,
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria C Thurnheer, MD
Organizational Affiliation
Department of Infectious Diseases, University Hospital Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Infectious Diseases, University Hospital Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Facility Name
Department of Urology, University Hopspital Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Optimized Perioperative Antibiotic Prophylaxis in Radical Cystectomy

We'll reach out to this number within 24 hrs